News Center
Share the latest news with you
2023
2023-06-15
Phase III Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors
Senaparib NDA Acceptance by the NMPA for first-line Maintenance Treatment of Patients with Advanced Ovarian Cancer
PARP1 Selective Inhibitor (IMP1734) Received IND Clearance from FDA
Entered into commercial partnership with Huadong Medicine for promoting Senaparib. Huadong Medicine received exclusive promotion rights of Senaparib in mainland China
About Us
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备2024107649号 互联网药品信息证书编号:(沪)-非经营性-2025-0012 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
